# Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Last Update: Apr 01, 2025
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
ClinicalTrials.gov Identifier:
NCT06785675
Novartis Reference Number:CAIN457AAE02
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region. This is a 24-week longitudinal single-arm prospective study based on data collected from EMRs along with patient-reported outcomes questionnaires (TSQM and DLQI) to evaluate patient-reported satisfaction and early quality of life experiences among HS patients who are newly initiated on Secukinumab. We will be using questionnaires at baseline and at week 24 to report on pre-defined outcomes in a representative HS population across the United Arab Emirates. The data will be collected using an electronic Case Report Form (eCRF) from both data sources (Electronic Medical Report and Questionnaires).

Condition
Hidradenitis Suppurativa
Overall Status
Recruiting
Number of Participants
60
Start Date
Mar 10, 2025
Completion Date
Nov 29, 2025
Gender
All
Age(s)
18 Years - 99 Years (Adult, Older Adult)

## Interventions

Other

### Secukinumab

This is an observational study. There is no treatment allocation.

## Eligibility Criteria

Inclusion Criteria:

* Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
* Male or Female adult patients ≥ 18 years of age at the time of data collection
* Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
* Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
* Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
* Agreed to sign an informed consent to be able to fill in the questionnaires.

Exclusion Criteria:

* Patients not fulfilling any of the abovementioned inclusion criteria.
* Patient's refusal to be included in the study or refusal to sign the informed consent.

**United Arab Emirates**

**Novartis Investigative Site**

Recruiting

Sharjah,United Arab Emirates

## Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

**Novartis Pharmaceuticals**

Phone: +41613241111
Email: novartis.email@novartis.com

---

**Source URL:** *https://prod1.novartis.com/clinicaltrials/study/nct06785675*

**List of links present in page**

1. https://clinicaltrials.gov/ct2/show/NCT06785675

2. #trial-eligibility
3. tel:+41613241111
4. mailto:novartis.email@novartis.com